Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, ...

The Global AI in Precision Medicine Market is expected to witness a growth rate of 25-30% in the next five ...

The Global Metaverse in Medical Training Market is expected to witness a growth rate of 8-9% in the next five years. Enhanced ...

The global Infusion Pump Market is valued at USD 17.99 billion in 2024 and is projected to reach a value of USD 31.56 billion ...

Inhaled Antifungals Market to Reach $450 Million by 2025, Fueled by Rising Adoption in Invasive Fungal Infections The global inhaled antifungals market is projected to reach $450 million in 2025, ...

‘DIADEME’ project awarded €6.5 million in government funding via France 2030, enabling Ciloa to advance development of its bio-drug APN-sEV (Adiponectin associated with exosomes), the world’s only ...

MMJ-001 Marks a Pharmaceutical First in Cannabis Medicine with FDA-Grade Formulation for a Devastating Neurological Disorder while awaiting final FDA approval for use in clinical trials. WASHINGTON, D ...

ANGLE plc celebrates 100 peer-reviewed studies validating its Parsortix® system, enhancing cancer diagnostics and personalised treatment strategies.

Live-In Care is the Solution to England’s Discharge CrisisAs NHS hospitals continue to face serious pressure from delayed discharges, Noble Live-In Care is calling for live-in care to be routinely ...

The AI in Life Science Market is anticipated to experience a remarkable compound annual growth rate (CAGR) of around 25% in the coming years, highlighting the increasing reliance on AI technologies ...

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that its drug Pepaxti has been included in new clinical practice guidelines ...

First patient dosed in the Phase I clinical trial of PulseSight Therapeutics’ PST-611 treatment for dry AMD/Geographic AtrophyParis, France, July 7th, 2025 – PulseSight Therapeutics SAS, an ...